These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 22075757

  • 1. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
    Wei Y, Zhang Z, Liao H, Wu L, Wu X, Zhou D, Xi X, Zhu Y, Feng Y.
    Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
    [Abstract] [Full Text] [Related]

  • 2. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
    Ge X, Guo R, Qiao Y, Zhang Y, Lei J, Wang X, Li L, Hu D.
    Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
    [Abstract] [Full Text] [Related]

  • 3. Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα).
    Tsai CL, Wu HM, Lin CY, Lin YJ, Chao A, Wang TH, Hsueh S, Lai CH, Wang HS.
    PLoS One; 2013 Jan; 8(9):e72999. PubMed ID: 24039841
    [Abstract] [Full Text] [Related]

  • 4. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway.
    Zhang J, Yang Y, Zhang Z, He Y, Liu Z, Yu Y, Wu S, Cai B, Feng Y.
    Cancer Lett; 2013 Oct 10; 339(2):279-87. PubMed ID: 23142288
    [Abstract] [Full Text] [Related]

  • 5. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2.
    Sun Y, Wang C, Yang H, Ma X.
    Eur J Cancer Prev; 2014 Sep 10; 23(5):418-24. PubMed ID: 25068805
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
    Chen Y, Li Z, He Y, Shang D, Pan J, Wang H, Chen H, Zhu Z, Wan L, Wang X.
    Toxicol Appl Pharmacol; 2014 Mar 01; 275(2):176-81. PubMed ID: 24440569
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells.
    Zhang H, Wang X, Chen Z, Wang W.
    Cell Mol Biol (Noisy-le-grand); 2015 Nov 30; 61(7):96-101. PubMed ID: 26638889
    [Abstract] [Full Text] [Related]

  • 15. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K/AKT pathway via di-demethylating H3K9 of cyclin D1.
    Chen C, Wang Y, Wang S, Liu Y, Zhang J, Xu Y, Zhang Z, Bao W, Wu S.
    Int J Oncol; 2017 Mar 30; 50(3):942-952. PubMed ID: 28098854
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
    He YY, Cai B, Yang YX, Liu XL, Wan XP.
    Cancer Sci; 2009 Jun 30; 100(6):1051-61. PubMed ID: 19432902
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.